FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 415 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type... August 5, 2024 ΚΑΡΚΙΝΟΣ ΗΠΑΤΟΣ December 10, 2018 FDA Approves Osimertinib with Platinum-Based Chemotherapy for EGFR-mutated Locally Advanced or... February 23, 2024 Study of More than Half a Million Women Links Regular Mammograms... March 10, 2021 Load more HOT NEWS Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... The Nobel Prize winner helping us treat children’s cancers
